Time: 10 AM EST | December 11, 2025

Interferon-gamma (IFNγ) plays a paradoxical role in CAR-T therapy—it’s essential for antitumor activity but can also limit CAR-T expansion and persistence, especially in CD28-based designs.

We are honored to host Dr. Bailey, who will present a cutting-edge strategy using cytokine-pathway editing to enhance CAR-T cell durability. By deleting the IFNγ receptor (IFNγR), this approach decouples efficacy from exhaustion, leading to more sustained antitumor responses across solid tumor models.

Key topics include:

• Leveraging cytokine-pathway editing to sustain CAR-T function
• Understanding costimulatory domain differences (CD28 vs. 4-1BB)
• Developing subset-aware strategies to optimize persistence and clinical translation

Join us to explore how fine-tuning cytokine sensing can unlock the full potential of CAR-T therapies against solid tumors.